IFITM1 and neoplasm: Aberrant expression of IFITM1 promotes tumor cell proliferation, inhibits cell death, stimulates invasion and metastasis, contributes to cancer cell resistance to endocrine therapy, chemotherapy and radiotherapy, and has prognostic value for patient outcomes (6,11,40).